⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

October 28, 2026Open Access

Which patient populations benefit most from long-acting injectable buprenorphine (Buvidal) regarding treatment retention and reduction in opioid use?

View Full Paper

Ask AI

Bookmark

Share

Abstract

Long-acting injectable buprenorphine (Buvidal) is shown to be effective in improving treatment retention and reducing opioid use in adults with opioid use disorder, although specific subpopulations deriving the most benefit are not clearly identified.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Tripdatabase (2026) studied this question.

synapsesocial.com/papers/6ae4335dd9418cd7c8f45da1 https://doi.org/10.5281/zenodo.23733995

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Retention and Other Efficacy Outcomes With Long-Acting Injectable Buprenorphine (Buvidal <sup>®</sup> ) in France: A National Retrospective Cross-Sectional Study (OPALE 2)Cross-Sectional Study · 2026
2Buvidal/Brixadi – a long-acting injectable buprenorphine formulation for the treatment of opioid dependence2025 · 5 citations
3What is the evidence for successful reduction and detoxification from Buvidal buprenorphine long-acting injection?Original Research · 2026
4Characteristics of patients who are initiated on long-acting buprenorphine (Buvidal®) in France: a retrospective cross-sectional study2024 · 2 citations
5Compared implementation of the long-acting buprenorphine treatment buvidal in four European countries2024 · 14 citations

Inpatient initiation of long-acting injectable buprenorphine for adolescents and young adults with opioid use disorder.2026
Buprenorphine Pharmacology Review: Update on Transmucosal and Long-acting Formulations2018
Seven‐day buprenorphine feasible in patients with minimal to mild opioid withdrawal2024